Board declares Interim Dividend
Alkem Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 09, 2018, inter alia, have declared Interim Dividend of Rs. 6/- (Rupees Six only) per equity share on the face value of Rs. 2/- per share for the financial year 2017-18.The date of payment of Interim Dividend shall be on and from February 23, 2018. Board Meeting-Outcome of Board Meeting
The Board of Directors of the Company, at its meeting held today, i.e. 9th February, 2018 inter alia, has: a. Approved the Standalone and Consolidated Unaudited Financial Results for the quarter and nine months ended 31st December, 2017. A copy of the said Financial Results and Limited Review Report of the Statutory Auditors of the Company are enclosed herewith.... Stempeutics ties up with Alkem Labs for phase-III trials for osteoarthritis product
Stemcell injection to hit market by 2020 Analyst / Investor Meet - Intimation
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we write to inform you that a conference call to discuss the Q3FY18 and 9MFY18 financial results will be held on Friday, 9th February, 2018 at 4.00 P.M. Please find attached herewith the conference call details. Kindly take note of the same. Record Date For The Purpose Of Payment Of Interim Dividend For The Financial Year 2017-2018.
The record date for the purpose of payment of interim dividend for the Financial Year 2017-2018, would be Tuesday, 20th February, 2018, subject to declaration of the said interim dividend by the Board of Directors in its meeting to be held on 9th February, 2018. Board to consider Interim Dividend
Alkem Laboratories Ltd has informed BSE that a meeting of the Board of Directors of the Company is scheduled to be held on February 09, 2018, inter alia: 1. To consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2017; and 2. To consider and approve Interim Dividend for the Financial Year 2017-2018. Notice Of Meeting Of Board Of Directors Of Alkem Laboratories Limited ('The Company')
Notice is hereby given to the Stock Exchanges under Regulation 29 read with Regulation 33 and Regulation 42 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 ('Listing Regulations') that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, 9th February, 2018, inter alia: (i) to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the... Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Basudeo N Singh Alkem Laboratories shares jump nearly 6%; m-cap up by Rs 15.23 billion
USFDA has issued an EIR for the company's manufacturing facility at Baddi, Himachal Pradesh, says Alkem Labs Press Release / Media Release
In furtherance to the intimation captioned "Update on US FDA Inspection at Alkem's Baddi Facility" dated 18th September, 2017, this is to inform you that US FDA has issued an Establishment Inspection Report (EIR) for the Company's manufacturing facility located at Baddi, India which was inspected from 11th September, 2017 to 15th September, 2017....